Featured Research

from universities, journals, and other organizations

New Study Links Common Cholesterol-Lowering Drugs To Reduced Prostate Cancer Risk

Date:
June 8, 2004
Source:
Oregon Health & Science University
Summary:
Men who take even small amounts of common cholesterol-lowering drugs such as Lovastatin and Simvastatin have a significantly reduced risk of prostate cancer, according to a new study by Oregon Health and Science University Cancer Institute researchers.

PORTLAND, Ore. — Men who take even small amounts of common cholesterol-lowering drugs such as Lovastatin and Simvastatin have a significantly reduced risk of prostate cancer, according to a new study by Oregon Health & Science University Cancer Institute researchers.

Related Articles


“If these results are confirmed in a larger prospective study, they may provide necessary evidence to consider the use of cholesterol-lowering drugs in prostate cancer prevention. Currently, no preventive measures are available for prostate cancer,” said Jackilen Shannon, Ph.D., R.D., a ssistant professor of public health and preventive medicine in the OHSU School of Medicine, member of the OHSU Cancer Institute and lead author of the study.

Shannon’s research suggests that men who have taken any amount of these drugs, known as statins, have a 58 percent lower risk of prostate cancer than men who have taken none at all. Shannon presented study results at the American Society for Clinical Oncology annual meeting in New Orleans, La., on June 6, 2004.

“We were interested in the relationship between statin use and prostate cancer because recent research has demonstrated that in a number of tumor types, statins also induce cancer cell death and growth arrest,” Shannon said.

Shannon and colleagues evaluated the association between statin use and prostate cancer risk in a population of older veterans enrolled in a case-control study of diet and prostate cancer risk.

“Our data suggest statins may also impact PSA production,” Shannon said. In addition to being associated with a reduced risk of prostate cancer, statins were associated with a 55 percent lower risk of an elevated prostate-specific antigen (PSA) level. Certain prostate conditions, including prostate cancer, can cause high levels of PSA in the blood. PSA levels are monitored to help predict the presence and progression of prostate cancer.

In a retrospective study, researchers reviewed records of men who were referred to a Veterans Affairs Medical Center for a prostate biopsy. Cases reviewed for this study include those of 72men diagnosed with prostate cancer, 150 who had negative biopsies, and 208 whose PSAs were normal. Data on their statin use was pulled from the Veterans Affairs’ electronic pharmacy database.

“Because the cases reviewed were part of a larger study of diet and prostate cancer risk that included extensive diet questionnaires, we were able to adjust our statin study data for many different factors, including cholesterol in the diet, and total fat and calorie intake,” Shannon said. Data also was adjusted for age, body mass index and race.

Statin prescriptions from 1997 to biopsy date were recorded. Data included date of initial prescription, date prescription discontinued or date of new prescription, daily dose and number of pills. The four most commonly used brands of statins were reviewed, including Lovastatin, Simvastatin, Fluvastatin and Atorvastatin. Researchers analyzed total days each statin was used at each prescribed does, cumulative dose of individual statins, average daily dose and total statin use. Statin data was merged with demographic data from the main case-control study.

“The VA’s electronic pharmacy provided a rich set of detailed data that allowed us to more accurately characterize the association between statins and prostate cancer risk,” Shannon said. “This data led us to unique findings about average daily statin dose and cumulative dose.”

When statin use was grouped by duration and dose, those with a cumulative dose of more than 19 grams had lower risk of prostate cancer. Those with an average daily dose of more than 40 milligrams were at a lower risk of an elevated PSA as compared to subjects with an average daily dose below 40 milligrams. These results remained consistent when individual types of statins were analyzed separately.

“While these data are suggestive, this is a pilot study limited by a small sample size and lack of control for additional comorbid factors,” Shannon said. “Further investigation is warranted.”

Prostate cancer is the most common cancer in men and the second leading cause of cancer-related death in American men. Overall, one in six men will develop prostate cancer during his lifetime.

This research was conducted as part of a study funded by the National Cancer Institute, a component of the National Institutes of Health.

Particulars: ASCO Abstract No. 4596, Statin use and prostate cancer risk


Story Source:

The above story is based on materials provided by Oregon Health & Science University. Note: Materials may be edited for content and length.


Cite This Page:

Oregon Health & Science University. "New Study Links Common Cholesterol-Lowering Drugs To Reduced Prostate Cancer Risk." ScienceDaily. ScienceDaily, 8 June 2004. <www.sciencedaily.com/releases/2004/06/040608065041.htm>.
Oregon Health & Science University. (2004, June 8). New Study Links Common Cholesterol-Lowering Drugs To Reduced Prostate Cancer Risk. ScienceDaily. Retrieved March 31, 2015 from www.sciencedaily.com/releases/2004/06/040608065041.htm
Oregon Health & Science University. "New Study Links Common Cholesterol-Lowering Drugs To Reduced Prostate Cancer Risk." ScienceDaily. www.sciencedaily.com/releases/2004/06/040608065041.htm (accessed March 31, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Tuesday, March 31, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Solitair Device Aims to Takes Guesswork out of Sun Safety

Solitair Device Aims to Takes Guesswork out of Sun Safety

Reuters - Innovations Video Online (Mar. 31, 2015) — The Solitair device aims to take the confusion out of how much sunlight we should expose our skin to. Small enough to be worn as a tie or hair clip, it monitors the user&apos;s sun exposure by taking into account their skin pigment, location and schedule. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins